VYGR - Voyager Therapeutics, Inc.
IEX Last Trade
5.89
0.030 0.509%
Share volume: 7,190
Last Updated: Thu 26 Dec 2024 08:30:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.86
0.03
0.51%
Fundamental analysis
25%
Profitability
25%
Dept financing
10%
Liquidity
75%
Performance
15%
Performance
5 Days
0.87%
1 Month
1.94%
3 Months
-1.87%
6 Months
-25.90%
1 Year
-33.64%
2 Year
3.96%
Key data
Stock price
$5.89
DAY RANGE
$5.68 - $5.88
52 WEEK RANGE
$5.38 - $11.72
52 WEEK CHANGE
-$34.39
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Alfred W. Sandrock
Region: US
Website: voyagertherapeutics.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: voyagertherapeutics.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease.
Recent news